Characteristics and prognosis of elderly-onset antiphospholipid syndrome: An observational cohort study

Abstract

Objective

Antiphospholipid syndrome (APS) is an autoimmune disease mainly affecting young individuals. Testing for antiphospholipid antibodies is recommended for young patients who are suspected to have APS. Yet, it is hard to differentiate APS from other acquired thrombophilia disorders in elderly-onset APS patients. This study aim to investigate the characteristics and prognosis of elderly-onset APS.

Methods

This is an observational cohort study. Thrombotic APS patients who underwent follow-ups between 2009 and 2022 were included. Elderly-onset APS patients (onset age ≥60 years) were compared to non-elderly-onset APS patients (onset age <60 years) and matched cases of elderly non-APS patients (age ≥60 years with thrombosis).

Results

A total of 161 APS patients were included in this study, 45 (28.0%) were elderly-onset APS. Stroke (35.6% vs. 18.1%, p = .018) was more common at disease onset in elderly-onset APS patients. Compared to non-elderly-onset patients, elderly-onset APS patients were associated with a higher number of cardiovascular risk factors. Elderly-onset APS patients showed significantly lower positive rate (51.1% vs. 71.6%, p = .014) and ratios [1.24 (1.01–1.38) vs. 1.37 (1.16–1.77), p = .004] of lupus anticoagulant. Elderly-onset APS patients had a significantly higher 10-years cumulative all-cause mortality (p < .001) and APS-related mortality than non-elderly-onset patients (p = .002) and elderly non-APS patients (p = .040).

Conclusions

Elderly-onset APS patients have unique disease characteristics with higher 10-years cumulative all-cause mortality and APS-related mortality. Early recognition and control of comorbidities may reduce the recurrence of thrombosis and mortality in elderly-onset APS patients.

Keywords

Antiphospholipid syndrome antiphospholipid antibodies thrombosis age of onset mortality

Get full access to this article

View all access options for this article.

References

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis 2006; 4: 295–306.

Petri

. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15: 145–151.

Cervera

Piette

Font

, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–1027.

Devreese

de Groot

de Laat

, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemostasis 2020; 18: 2828–2839.

Tektonidou

Andreoli

Limper

, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78: 1296–1304.

Yelnik

Erton

Drumez

, et al. Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository (“Registry”). Semin Arthritis Rheum 2024; 65: 152347.

Masson

An Nguyen

Dufrost

, et al. Antiphospholipid syndrome in patients over 65 years: a comparative study of clinical and biological features and thrombotic relapses. Lupus 2022; 31: 1816–1823.

Grimaud

Yelnik

Pineton de Chambrun

, et al. Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study. Rheumatology 2019; 58: 1006–1010.

Devreese

Ortel

Pengo

, et al. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemostasis 2018; 16: 809–813.

10.

Radin

Schreiber

Costanzo

, et al. The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. Int J Cardiol 2017; 240: 72.

11.

Erkan

Derksen

Levy

, et al. Antiphospholipid syndrome clinical research task force report. Lupus 2011; 20: 219–224.

12.

Almirall

. Sodium excretion, cardiovascular disease, and chronic kidney disease. J Am Med Assoc 2016; 316: 1112.

13.

Gansevoort

Correa-Rotter

Hemmelgarn

, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339–352.

14.

Balbi

Ahmadzadeh

Tektonidou

, et al. Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry. Rheumatology 2024; 63: 772.

15.

Nalli

Andreoli

Casu

, et al. Management of recurrent thrombosis in antiphospholipid syndrome. Curr Rheumatol Rep 2014; 16: 405.

16.

da Silva

Levy

de Carvalho

. Cardiovascular risk factors in the antiphospholipid syndrome. J Immunol Res 2014; 2014: 621270.

17.

Gaspar

Farinha

Sayar

, et al. A one-point increase in the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality in thrombotic antiphospholipid syndrome. Clin Exp Rheumatol 2022; 41: 605–612.

18.

Cervera

Serrano

Pons-Estel

, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74: 1011.

19.

Wincup

Ioannou

. The differences between childhood and adult onset antiphospholipid syndrome. Front Pediatr 2018; 6: 362.

20.

Rothberg

Celestin

Fiore

, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: 241–250.

21.

Andreotti

Testa

Biondi-Zoccai

, et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27: 519–526.

22.

Ordi-Ros

Sáez-Comet

Pérez-Conesa

, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019; 171: 685–694.

23.

Woller

Stevens

Kaplan

, et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv 2022; 6: 1661–1670.

24.

Adelhelm

Christensen

Balbi

, et al. Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials. Lupus Sci Med 2023; 10: e001018.

25.

Dufrost

Risse

Reshetnyak

, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 2018; 17: 1011–1021.

26.

Balbi

Pacheco

Monticielo

, et al. Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). Adv Rheumatol 2020; 60: 29.

27.

Bejjani

Khairani

Assi

, et al. When direct oral anticoagulants should not Be standard treatment: JACC state-of-the-art review. J Am Coll Cardiol 2024; 83: 444–465.

28.

Konstantinides

Meyer

Becattini

, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020;41:543–603.

29.

Ortel

Neumann

Ageno

, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4: 4693–4738.

30.

Arachchillage

Gomez

Alikhan

, et al. Addendum to British society for haematology guidelines on investigation and management of antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants. Br J Haematol 2020; 189: 212.

31.

Grika

Ziakas

Zintzaras

, et al. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol 2012; 39: 516–523.

32.

Ames

Merashli

Chis Ster

, et al. Survival in primary antiphospholipid syndrome. A single-centre cohort study. Thromb Haemostasis 2016; 115: 1200.

33.

Piazza

Seddighzadeh

Goldhaber

. Deep-vein thrombosis in the elderly. Clin Appl Thromb Hemost 2008; 14: 393.

34.

Piazza

Goldhaber

. The acutely decompensated right ventricle: pathways for diagnosis and management. Chest 2005; 128: 1836–1852.

35.

Wang

Yin

, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care 2020; 24: 188.

36.

Yoo

Jang

Cha

, et al. Comparison of mortality, length of hospital stay and transfusion between hemiarthroplasty and total hip arthroplasty in octo- and nonagenarian patients with femoral neck fracture: a nationwide study in korea. J Kor Med Sci 2021; 36: e300.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.10 MB